$IMSC - Implant Sciences nabs another China order:

Implant Sciences Sells QS-H150 Explosives Trace Detectors for Nuclear Power Plant Protection in China

WILMINGTON, Mass., Nov. 6, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today it has sold multiple units of its QS-H150 handheld explosives trace detectors to a customer in China. The units will be deployed across several locations for the purpose of protecting nuclear power plants in multi-layered security environments.

"We've been selling our QS-H150s in China since 2005, and during that time they have earned a well-deserved reputation for superior performance. QS-H150s are trusted for use in the most mission-critical settings," stated Implant Sciences' Vice President of Sales and Marketing, Darryl Jones. "In the past Implant Sciences has provided QS-H150s for nuclear power plant protection in other countries such as Japan and Spain. We are pleased to announce this sale which marks the first such deployment in China."

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In October 2013, the Company became the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification and a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.


Contact:

Implant Sciences CorporationCompany Contact:Glenn Bolduc, CEO978-752-1700 or

Investor Contact:Laurel Moody646-810-0608



SOURCE Implant Sciences Corporation

$IMSC - Implant Sciences nabs another China order:

Implant Sciences Sells QS-H150 Explosives Trace Detectors for Nuclear Power Plant Protection in China

WILMINGTON, Mass., Nov. 6, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today it has sold multiple units of its QS-H150 handheld explosives trace detectors to a customer in China. The units will be deployed across several locations for the purpose of protecting nuclear power plants in multi-layered security environments.

"We've been selling our QS-H150s in China since 2005, and during that time they have earned a well-deserved reputation for superior performance. QS-H150s are trusted for use in the most mission-critical settings," stated Implant Sciences' Vice President of Sales and Marketing, Darryl Jones. "In the past Implant Sciences has provided QS-H150s for nuclear power plant protection in other countries such as Japan and Spain. We are pleased to announce this sale which marks the first such deployment in China."

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In October 2013, the Company became the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification and a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.


Contact:

Implant Sciences CorporationCompany Contact:Glenn Bolduc, CEO978-752-1700 or

Investor Contact:Laurel Moody646-810-0608



SOURCE Implant Sciences Corporation

Let the order flow commence!!

$IMSC - Implant Sciences lands MAJOR Latin American ETD order:

Implant Sciences Sells QS-B220 Explosives Trace Detectors for use at 19 Airports

WILMINGTON, Mass., Nov. 5, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 explosives trace detectors have been sold to a federal agency in charge of operating 19 airports in one Latin American country. The units will be used for checkpoint screening and air cargo screening.

"With this deployment, our QS-B220 has become the system of choice in explosives trace detection devices for these 19 airports. This is a major milestone for Implant Sciences and gives the Company a significant presence in the Latin American aviation security market," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "The QS-B220 was selected based on its favorable total cost of ownership, superior performance capabilities, and its regulatory certifications."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In October 2013, the Company became the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700

or

Investor Contact:
Laurel Moody
646-810-0608

http://finance.yahoo.com/news/implant-sciences-sells-qs-b220-120000576.html

$IMSC - Implant Sciences lands MAJOR Latin American ETD order:

Implant Sciences Sells QS-B220 Explosives Trace Detectors for use at 19 Airports

WILMINGTON, Mass., Nov. 5, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 explosives trace detectors have been sold to a federal agency in charge of operating 19 airports in one Latin American country. The units will be used for checkpoint screening and air cargo screening.

"With this deployment, our QS-B220 has become the system of choice in explosives trace detection devices for these 19 airports. This is a major milestone for Implant Sciences and gives the Company a significant presence in the Latin American aviation security market," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "The QS-B220 was selected based on its favorable total cost of ownership, superior performance capabilities, and its regulatory certifications."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In October 2013, the Company became the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700

or

Investor Contact:
Laurel Moody
646-810-0608

http://finance.yahoo.com/news/implant-sciences-sells-qs-b220-120000576.html

$IMSC - Implant Sciences lands MAJOR Latin American ETD order:

Implant Sciences Sells QS-B220 Explosives Trace Detectors for use at 19 Airports

WILMINGTON, Mass., Nov. 5, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 explosives trace detectors have been sold to a federal agency in charge of operating 19 airports in one Latin American country. The units will be used for checkpoint screening and air cargo screening.

"With this deployment, our QS-B220 has become the system of choice in explosives trace detection devices for these 19 airports. This is a major milestone for Implant Sciences and gives the Company a significant presence in the Latin American aviation security market," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "The QS-B220 was selected based on its favorable total cost of ownership, superior performance capabilities, and its regulatory certifications."

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In October 2013, the Company became the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700

or

Investor Contact:
Laurel Moody
646-810-0608

http://finance.yahoo.com/news/implant-sciences-sells-qs-b220-120000576.html

TSA agent wounded in shooting at LAX

A shooting occurred at Los Angeles International Airport Friday morning.

Posted By Gabrielle Levy | Nov. 1, 2013 | 1:08 PM

(UPI) -- At least one airport worker was wounded at Los Angeles International Airport Friday when a shooter entered Terminal 3 of the airport and opened fire.

At least one of the injured people appeared to be a TSA agent, but the victim's condition is unknown. Eyewitnesses describe a man carrying a rifle who had passed the security checkpoint and was moving through the airport.

Officials from LAX said the incident began around 9:30 a.m. The location or condition of the suspect is unknown.

Terminals 2 and 3 were evacuated when multiple shots rang out at the airport, as was Century Boulevard. Terminal 3 serves Allegiant Air, Frontier, JetBlue, Spirit and Virgin America.

Read more: http://www.upi.com/blog/2013/11/01/TSA-agent-wounded-in-shooting-at-LAX/1611383325719/#ixzz2jPrWFAhY

LAPD Tweeting that LAPD is now on TACTICAL ALERT due to a major incident @LAPDPacific #LAX @LAX_Official #poltwt

CNBC reporting that LAX has been evacuated.

The TSA is opening up its purse strings:

MIA Gets Multi-Million Dollar Grant From TSA

Posted Friday, November 1st 2013 @ 4am

Miami International Airport is hoping a multi-million dollar grant will be able to streamline passenger baggage in the coming years.

The T-S-A issued a $100 million grant to the aiport, which will be used to install new baggage screening systems over the next five years.

Aiport spokesperson Marc Henderson says the new system will be capable of screening close to 800-bags per hour, which is double the normal screening process.

This is the 2nd largest grant ever issued by TSA.

Read more: http://www.wiod.com/articles/wiodam-local-news-122821/mia-gets-multimillion-dollar-grant-from-11788927/#ixzz2jOv5yZLc

$IMSC - Implant Sciences to Exhibit QS-B220 at Air Cargo Americas
1:05 PM ET, 10/31/2013 - PR Newswire

WILMINGTON, Mass., Oct. 31, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it will exhibit its QS-B220 desktop explosives and drugs trace detectors at Air Cargo Americas on November 6th through 8th in Miami, Florida at booth #929.

Implant Sciences' QS-B220 has recently been added to the "Qualified" section of the Air Cargo Screening Technology List (ACSTL), joining the list of products from which the TSA encourages regulated customers to purchase. Carriers and freight forwarders now have the option of deploying a screening technology that is free from radioactive materials and emits no ionizing radiation.

Only equipment listed on the ACSTL can be used for screening cargo carried on passenger planes landing or taking off from American airports. Additionally, many other countries accept TSA qualification when making purchase decisions.

"Air Cargo Americas is a great venue for us to highlight our QS-B220. Our system is recognized in the air cargo screening field as the new standard in trace detection," stated Todd Swearingen, General Manager, Americas for Implant Sciences. "A number of prospective buyers have heard from our current users that the QS-B220 is technologically superior to the competition. We look forward to demonstrating the product's competitive advantages to buyers throughout the Americas."

"This is a critical and exciting time for Implant Sciences. The QS-B220 has achieved a string of regulatory successes so far this year, and our systems have built a reputation for being easy-to-use and low-cost to maintain. We believe that an investment in trade shows and exhibitions this fall will help us capitalize on this momentum and increase our market share," stated Implant Sciences' President and CEO, Glenn D. Bolduc.

The 2011, Air Cargo Americas International Congress and Exhibition was the largest air cargo exhibition in the Western Hemisphere, with 6,903 international aviation and maritime business executives from 65 countries visiting the exhibition. According to Air Cargo Americas, at the Air Cargo & Sea Cargo Americas 2011 exhibition, more than $101 million in actual and projected sales were reported by exhibitors.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In October 2013, the Company became the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences CorporationCompany Contact:Glenn Bolduc, CEO978-752-1700

or

Investor Contact:Laurel Moody646-810-0608

SOURCE Implant Sciences Corporation

$IMSC - Implant Sciences to Exhibit QS-B220 at Air Cargo Americas
1:05 PM ET, 10/31/2013 - PR Newswire

WILMINGTON, Mass., Oct. 31, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it will exhibit its QS-B220 desktop explosives and drugs trace detectors at Air Cargo Americas on November 6th through 8th in Miami, Florida at booth #929.

Implant Sciences' QS-B220 has recently been added to the "Qualified" section of the Air Cargo Screening Technology List (ACSTL), joining the list of products from which the TSA encourages regulated customers to purchase. Carriers and freight forwarders now have the option of deploying a screening technology that is free from radioactive materials and emits no ionizing radiation.

Only equipment listed on the ACSTL can be used for screening cargo carried on passenger planes landing or taking off from American airports. Additionally, many other countries accept TSA qualification when making purchase decisions.

"Air Cargo Americas is a great venue for us to highlight our QS-B220. Our system is recognized in the air cargo screening field as the new standard in trace detection," stated Todd Swearingen, General Manager, Americas for Implant Sciences. "A number of prospective buyers have heard from our current users that the QS-B220 is technologically superior to the competition. We look forward to demonstrating the product's competitive advantages to buyers throughout the Americas."

"This is a critical and exciting time for Implant Sciences. The QS-B220 has achieved a string of regulatory successes so far this year, and our systems have built a reputation for being easy-to-use and low-cost to maintain. We believe that an investment in trade shows and exhibitions this fall will help us capitalize on this momentum and increase our market share," stated Implant Sciences' President and CEO, Glenn D. Bolduc.

The 2011, Air Cargo Americas International Congress and Exhibition was the largest air cargo exhibition in the Western Hemisphere, with 6,903 international aviation and maritime business executives from 65 countries visiting the exhibition. According to Air Cargo Americas, at the Air Cargo & Sea Cargo Americas 2011 exhibition, more than $101 million in actual and projected sales were reported by exhibitors.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In October 2013, the Company became the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences CorporationCompany Contact:Glenn Bolduc, CEO978-752-1700

or

Investor Contact:Laurel Moody646-810-0608

SOURCE Implant Sciences Corporation

$IMSC - Implant Sciences to Exhibit QS-B220 at Air Cargo Americas
1:05 PM ET, 10/31/2013 - PR Newswire

WILMINGTON, Mass., Oct. 31, 2013 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that it will exhibit its QS-B220 desktop explosives and drugs trace detectors at Air Cargo Americas on November 6th through 8th in Miami, Florida at booth #929.

Implant Sciences' QS-B220 has recently been added to the "Qualified" section of the Air Cargo Screening Technology List (ACSTL), joining the list of products from which the TSA encourages regulated customers to purchase. Carriers and freight forwarders now have the option of deploying a screening technology that is free from radioactive materials and emits no ionizing radiation.

Only equipment listed on the ACSTL can be used for screening cargo carried on passenger planes landing or taking off from American airports. Additionally, many other countries accept TSA qualification when making purchase decisions.

"Air Cargo Americas is a great venue for us to highlight our QS-B220. Our system is recognized in the air cargo screening field as the new standard in trace detection," stated Todd Swearingen, General Manager, Americas for Implant Sciences. "A number of prospective buyers have heard from our current users that the QS-B220 is technologically superior to the competition. We look forward to demonstrating the product's competitive advantages to buyers throughout the Americas."

"This is a critical and exciting time for Implant Sciences. The QS-B220 has achieved a string of regulatory successes so far this year, and our systems have built a reputation for being easy-to-use and low-cost to maintain. We believe that an investment in trade shows and exhibitions this fall will help us capitalize on this momentum and increase our market share," stated Implant Sciences' President and CEO, Glenn D. Bolduc.

The 2011, Air Cargo Americas International Congress and Exhibition was the largest air cargo exhibition in the Western Hemisphere, with 6,903 international aviation and maritime business executives from 65 countries visiting the exhibition. According to Air Cargo Americas, at the Air Cargo & Sea Cargo Americas 2011 exhibition, more than $101 million in actual and projected sales were reported by exhibitors.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In October 2013, the Company became the third ETD manufacturer, and the sole American-owned company, to currently have product qualification from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences CorporationCompany Contact:Glenn Bolduc, CEO978-752-1700

or

Investor Contact:Laurel Moody646-810-0608

SOURCE Implant Sciences Corporation

$IMSC is the next $TASR IMO. Just as TASR's safety technology has monopolized law enforcement agencies so too will IMSC's Quantum Sniffers monopolize the ETD space.

$IMSC is the next $TASR IMO. Just as TASR's safety technology has monopolized law enforcement agencies so too will IMSC's Quantum Sniffers monopolize the ETD space.

$IMSC is the next $TASR IMO. Just as TASR's safety technology has monopolized law enforcement agencies so too will IMSC's Quantum Sniffers monopolize the ETD space.

$IMSC could be the next $TASR IMO. Some security equipment stock metrics:

Today TASR reported favorable quarterly EPS. If you annualize their latest quarterly revenues and EPS, TASR's annualized revenue roll is $140 Million and annualized EPS is $0.40. With 53.3 Million fully diluted shares that results in a market cap approaching $1 Billion and a forward P/E ratio of 45.1 times.

IMO it won't be long until IMSC will be showing the same kind of metrics as it begins to dominate the explosive trace detection space.

$IMSC could be the next $TASR IMO. Some security equipment stock metrics:

Today TASR reported favorable quarterly EPS. If you annualize their latest quarterly revenues and EPS, TASR's annualized revenue roll is $140 Million and annualized EPS is $0.40. With 53.3 Million fully diluted shares that results in a market cap approaching $1 Billion and a forward P/E ratio of 45.1 times.

IMO it won't be long until IMSC will be showing the same kind of metrics as it begins to dominate the explosive trace detection space.

$IMSC could be the next $TASR IMO. Some security equipment stock metrics:

Today TASR reported favorable quarterly EPS. If you annualize their latest quarterly revenues and EPS, TASR's annualized revenue roll is $140 Million and annualized EPS is $0.40. With 53.3 Million fully diluted shares that results in a market cap approaching $1 Billion and a forward P/E ratio of 45.1 times.

IMO it won't be long until IMSC will be showing the same kind of metrics as it begins to dominate the explosive trace detection space.

Some security equipment stock metrics:

Today TASR reported favorable quarterly EPS. If you annualize their latest quarterly revenues and EPS, TASR annualized revenue roll is $140 Million and annualized EPS is $0.40. With 53.3 Million fully diluted shares that results in a market cap approaching $1 Billion and a forward P/E ratio of 45.1 times.

IMO it won't be long until IMSC will be showing the same kind of metrics as it begins to dominate the ETD space.

$IMSC - Implant Sciences from UPI:

Explosives detector makes TSA 'qualified' list

WILMINGTON, Mass., Oct. 28 (UPI) -- An explosives detector by Implant Sciences has been added to the U.S. Transportation Security Administration's list of qualified security solutions.
The "qualified" status, which follows an earlier "approved" status and additional testing, means regulated organizations are encouraged to procure the product, the company said.

"This is the fourth regulatory success Implant Sciences has had with the QS-B220 this year," Implant Sciences Vice President of Technology Todd Silvestri said. "Through these government approvals and successes with a number of air cargo customers, the QS-B220 has proven its efficacy in air cargo screening facilities was well as in the laboratory."

Implant Science's QS-B220 uses ion mobility spectrometry to rapidly detect and identify trace amounts of a wide variety of military, commercial and homemade explosives. It features a radioactive material-free design, push-button maintenance and diagnostics, and a patented internal automatic calibration system.

"Implant Sciences is proud to be the only provider of a TSA-qualified trace detection solution that does not incorporate radioactive materials," said Glenn D. Bolduc, the company's president and chief executive officer "Not having to invest in radiation safety protocols represents a significant operational advantage for many of our customers. We anticipate that this achievement will accelerate our sales efforts, both domestically and internationally."


© 2013 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.


Read more: http://www.upi.com/Business_News/Security-Industry/2013/10/28/Explosives-detector-makes-TSA-qualified-list/UPI-77921382989646/#ixzz2j7WWH1td

$IMSC - Implant Sciences from UPI:

Explosives detector makes TSA 'qualified' list

WILMINGTON, Mass., Oct. 28 (UPI) -- An explosives detector by Implant Sciences has been added to the U.S. Transportation Security Administration's list of qualified security solutions.
The "qualified" status, which follows an earlier "approved" status and additional testing, means regulated organizations are encouraged to procure the product, the company said.

"This is the fourth regulatory success Implant Sciences has had with the QS-B220 this year," Implant Sciences Vice President of Technology Todd Silvestri said. "Through these government approvals and successes with a number of air cargo customers, the QS-B220 has proven its efficacy in air cargo screening facilities was well as in the laboratory."

Implant Science's QS-B220 uses ion mobility spectrometry to rapidly detect and identify trace amounts of a wide variety of military, commercial and homemade explosives. It features a radioactive material-free design, push-button maintenance and diagnostics, and a patented internal automatic calibration system.

"Implant Sciences is proud to be the only provider of a TSA-qualified trace detection solution that does not incorporate radioactive materials," said Glenn D. Bolduc, the company's president and chief executive officer "Not having to invest in radiation safety protocols represents a significant operational advantage for many of our customers. We anticipate that this achievement will accelerate our sales efforts, both domestically and internationally."


© 2013 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.


Read more: http://www.upi.com/Business_News/Security-Industry/2013/10/28/Explosives-detector-makes-TSA-qualified-list/UPI-77921382989646/#ixzz2j7WWH1td

$IMSC - Implant Sciences from UPI:

Explosives detector makes TSA 'qualified' list

WILMINGTON, Mass., Oct. 28 (UPI) -- An explosives detector by Implant Sciences has been added to the U.S. Transportation Security Administration's list of qualified security solutions.
The "qualified" status, which follows an earlier "approved" status and additional testing, means regulated organizations are encouraged to procure the product, the company said.

"This is the fourth regulatory success Implant Sciences has had with the QS-B220 this year," Implant Sciences Vice President of Technology Todd Silvestri said. "Through these government approvals and successes with a number of air cargo customers, the QS-B220 has proven its efficacy in air cargo screening facilities was well as in the laboratory."

Implant Science's QS-B220 uses ion mobility spectrometry to rapidly detect and identify trace amounts of a wide variety of military, commercial and homemade explosives. It features a radioactive material-free design, push-button maintenance and diagnostics, and a patented internal automatic calibration system.

"Implant Sciences is proud to be the only provider of a TSA-qualified trace detection solution that does not incorporate radioactive materials," said Glenn D. Bolduc, the company's president and chief executive officer "Not having to invest in radiation safety protocols represents a significant operational advantage for many of our customers. We anticipate that this achievement will accelerate our sales efforts, both domestically and internationally."


© 2013 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.


Read more: http://www.upi.com/Business_News/Security-Industry/2013/10/28/Explosives-detector-makes-TSA-qualified-list/UPI-77921382989646/#ixzz2j7WWH1td

From United Press International:

Explosives detector makes TSA 'qualified' list

WILMINGTON, Mass., Oct. 28 (UPI) -- An explosives detector by Implant Sciences has been added to the U.S. Transportation Security Administration's list of qualified security solutions.
The "qualified" status, which follows an earlier "approved" status and additional testing, means regulated organizations are encouraged to procure the product, the company said.

"This is the fourth regulatory success Implant Sciences has had with the QS-B220 this year," Implant Sciences Vice President of Technology Todd Silvestri said. "Through these government approvals and successes with a number of air cargo customers, the QS-B220 has proven its efficacy in air cargo screening facilities was well as in the laboratory."

Implant Science's QS-B220 uses ion mobility spectrometry to rapidly detect and identify trace amounts of a wide variety of military, commercial and homemade explosives. It features a radioactive material-free design, push-button maintenance and diagnostics, and a patented internal automatic calibration system.

"Implant Sciences is proud to be the only provider of a TSA-qualified trace detection solution that does not incorporate radioactive materials," said Glenn D. Bolduc, the company's president and chief executive officer "Not having to invest in radiation safety protocols represents a significant operational advantage for many of our customers. We anticipate that this achievement will accelerate our sales efforts, both domestically and internationally."


© 2013 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.


Read more: http://www.upi.com/Business_News/Security-Industry/2013/10/28/Explosives-detector-makes-TSA-qualified-list/UPI-77921382989646/#ixzz2j7WWH1td

$IMSC - Implant Sciences' TSA qualification of its non-radioactive air cargo bomb detection equipment reminds me of biotech stocks receiving FDA approvals. With biotechs you sometimes see doubles or triples in their stock prices in short order. Which leads me to the conclusion that despite this great TSA news today the market is somewhat skeptical of IMSC landing significant orders. I believe they will and this is a great time to accumulate. All IMHO.

I was thinking the same thing except with biotechs receiving FDA approvals you sometimes see doubles or triples in their stock prices in short order. Which leads me to the conclusion that despite this great TSA qualification the market is somewhat skeptical of IMSC landing significant orders. I believe they will and this is a great time to accumulate. All IMHO.

Open the order floodgates!

Most importantly IMSC's products are non-radioactive unlike Smiths and Morpho, the main competitors which dominate this space.

$IMSC - Implant Sciences' products are non-radioactive unlike Smiths and Morpho, the main competitors which dominate this space.

$IMSC - Implant Sciences' products are non-radioactive unlike Smiths and Morpho, the main competitors which dominate this space.

$IMSC - Implant Sciences' products are non-radioactive unlike Smiths and Morpho, the main competitors which dominate this space.

$IMSC - Implant Sciences on the upmove following its QS-B220 Explosives Trace Detector receiving "Qualified" Status for Air Cargo.

Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp. (IMSC) Price Crossed Above Its 60 Day Moving Average

IMSC crossed above its 60 day moving average of $1.12 with a trade of $1.14 at 11:01 AM EDT, up 1.8% from the moving average. It is currently trading higher on the day, up 1.8% to $1.14, on volume of 27,050, which is especially heavy given that there are still several hours left in the trading day.

Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.

$IMSC - Implant Sciences on the upmove following its QS-B220 Explosives Trace Detector receiving "Qualified" Status for Air Cargo.

Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp. (IMSC) Price Crossed Above Its 60 Day Moving Average

IMSC crossed above its 60 day moving average of $1.12 with a trade of $1.14 at 11:01 AM EDT, up 1.8% from the moving average. It is currently trading higher on the day, up 1.8% to $1.14, on volume of 27,050, which is especially heavy given that there are still several hours left in the trading day.

Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.

$IMSC - Implant Sciences on the upmove following its QS-B220 Explosives Trace Detector receiving "Qualified" Status for Air Cargo.

Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp. (IMSC) Price Crossed Above Its 60 Day Moving Average

IMSC crossed above its 60 day moving average of $1.12 with a trade of $1.14 at 11:01 AM EDT, up 1.8% from the moving average. It is currently trading higher on the day, up 1.8% to $1.14, on volume of 27,050, which is especially heavy given that there are still several hours left in the trading day.

Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.

Alert Triggered for Implant Sciences Corp.
Implant Sciences Corp. (IMSC) Price Crossed Above Its 60 Day Moving Average

IMSC crossed above its 60 day moving average of $1.12 with a trade of $1.14 at 11:01 AM EDT, up 1.8% from the moving average. It is currently trading higher on the day, up 1.8% to $1.14, on volume of 27,050, which is especially heavy given that there are still several hours left in the trading day.

Please note you will receive only one "Price Crosses its Moving Average" alert per day per stock which means that you will not get another 60 day moving average alert for IMSC.

$CONX - Corgenix Medical Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.

Multi-year collaboration is based on Corgenix’ proprietary atherosclerotic cardiovascularbiomarker technology

DENVER--(BUSINESS WIRE)--Oct. 28, 2013-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.

Under terms of the multi-year agreement, HDL, Inc. has the rights to use Corgenix technology to develop, validate and offer a clinical LDT that may assist clinicians in predicting an increased risk for heart disease in various patient populations. The initial term of the agreement is three years, with annual renewals thereafter based on certain performance requirements.

“This strategic partnership continues our path to fully realize the commercial value of our technology,” said Douglass Simpson, President and CEO of Corgenix. “Our company looks forward to this beneficial partnership, which aims to expand the clinical utility of this advanced cardiac disease biomarker.”

“Our partnership with Corgenix fits perfectly with our strategy to develop best-of-breed biomarkers for the most comprehensive risk factor testing for cardiovascular disease and related diseases,” said Tonya Mallory, President and CEO of HDL, Inc.

LDT’s are at the leading edge of the personalized medicine movement, which includes testing that enables targeted pharmacologic treatment for, and prevention of, heart disease, cancer and other diseases.

Corgenix originally licensed the technology in 2002, and has applied this proprietary technology to the FDA-cleared anti-AtherOx® IgG test kit.

About Health Diagnostic Laboratory, Inc.

Founded in 2008, Health Diagnostic Laboratory, Inc. (HDL, Inc.) is a leader in health management offering a comprehensive test menu of biomarkers of risk factors for cardiovascular disease, diabetes, and related diseases. HDL, Inc.’s systematic approach identifies factors contributing to disease and provides a basis for effective treatment, allowing physicians to more effectively manage patients. Individuals receive a personalized overview of their risk factors along with intensive counseling from expert Clinical Health Consultants at no additional cost, improving compliance and enhancing satisfaction. HDL, Inc. is a CLIA-certified, CAP-accredited laboratory. For more information, visit myhdl.com, and make HDL, Inc. part of your digital lifestyle at Facebook.com/myhdl and Twitter.com/hdltweets.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factorsthat would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Source: Corgenix Medical Corp.

Corgenix Medical Corp.Company Contact:Corgenix Medical Corp.William Critchfield, 303-453-8903Senior VP and CFOwcritchfield@corgenix.comorMedia Contact:Armada Medical MarketingDan Snyders, 303-623-1190 x230Vice President and Public Relations Supervisordan@armadamedical.com

$CONX - Corgenix Medical Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.

Multi-year collaboration is based on Corgenix’ proprietary atherosclerotic cardiovascularbiomarker technology

DENVER--(BUSINESS WIRE)--Oct. 28, 2013-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.

Under terms of the multi-year agreement, HDL, Inc. has the rights to use Corgenix technology to develop, validate and offer a clinical LDT that may assist clinicians in predicting an increased risk for heart disease in various patient populations. The initial term of the agreement is three years, with annual renewals thereafter based on certain performance requirements.

“This strategic partnership continues our path to fully realize the commercial value of our technology,” said Douglass Simpson, President and CEO of Corgenix. “Our company looks forward to this beneficial partnership, which aims to expand the clinical utility of this advanced cardiac disease biomarker.”

“Our partnership with Corgenix fits perfectly with our strategy to develop best-of-breed biomarkers for the most comprehensive risk factor testing for cardiovascular disease and related diseases,” said Tonya Mallory, President and CEO of HDL, Inc.

LDT’s are at the leading edge of the personalized medicine movement, which includes testing that enables targeted pharmacologic treatment for, and prevention of, heart disease, cancer and other diseases.

Corgenix originally licensed the technology in 2002, and has applied this proprietary technology to the FDA-cleared anti-AtherOx® IgG test kit.

About Health Diagnostic Laboratory, Inc.

Founded in 2008, Health Diagnostic Laboratory, Inc. (HDL, Inc.) is a leader in health management offering a comprehensive test menu of biomarkers of risk factors for cardiovascular disease, diabetes, and related diseases. HDL, Inc.’s systematic approach identifies factors contributing to disease and provides a basis for effective treatment, allowing physicians to more effectively manage patients. Individuals receive a personalized overview of their risk factors along with intensive counseling from expert Clinical Health Consultants at no additional cost, improving compliance and enhancing satisfaction. HDL, Inc. is a CLIA-certified, CAP-accredited laboratory. For more information, visit myhdl.com, and make HDL, Inc. part of your digital lifestyle at Facebook.com/myhdl and Twitter.com/hdltweets.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factorsthat would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Source: Corgenix Medical Corp.

Corgenix Medical Corp.Company Contact:Corgenix Medical Corp.William Critchfield, 303-453-8903Senior VP and CFOwcritchfield@corgenix.comorMedia Contact:Armada Medical MarketingDan Snyders, 303-623-1190 x230Vice President and Public Relations Supervisordan@armadamedical.com

$CONX - Corgenix Medical Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.

Multi-year collaboration is based on Corgenix’ proprietary atherosclerotic cardiovascularbiomarker technology

DENVER--(BUSINESS WIRE)--Oct. 28, 2013-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.

Under terms of the multi-year agreement, HDL, Inc. has the rights to use Corgenix technology to develop, validate and offer a clinical LDT that may assist clinicians in predicting an increased risk for heart disease in various patient populations. The initial term of the agreement is three years, with annual renewals thereafter based on certain performance requirements.

“This strategic partnership continues our path to fully realize the commercial value of our technology,” said Douglass Simpson, President and CEO of Corgenix. “Our company looks forward to this beneficial partnership, which aims to expand the clinical utility of this advanced cardiac disease biomarker.”

“Our partnership with Corgenix fits perfectly with our strategy to develop best-of-breed biomarkers for the most comprehensive risk factor testing for cardiovascular disease and related diseases,” said Tonya Mallory, President and CEO of HDL, Inc.

LDT’s are at the leading edge of the personalized medicine movement, which includes testing that enables targeted pharmacologic treatment for, and prevention of, heart disease, cancer and other diseases.

Corgenix originally licensed the technology in 2002, and has applied this proprietary technology to the FDA-cleared anti-AtherOx® IgG test kit.

About Health Diagnostic Laboratory, Inc.

Founded in 2008, Health Diagnostic Laboratory, Inc. (HDL, Inc.) is a leader in health management offering a comprehensive test menu of biomarkers of risk factors for cardiovascular disease, diabetes, and related diseases. HDL, Inc.’s systematic approach identifies factors contributing to disease and provides a basis for effective treatment, allowing physicians to more effectively manage patients. Individuals receive a personalized overview of their risk factors along with intensive counseling from expert Clinical Health Consultants at no additional cost, improving compliance and enhancing satisfaction. HDL, Inc. is a CLIA-certified, CAP-accredited laboratory. For more information, visit myhdl.com, and make HDL, Inc. part of your digital lifestyle at Facebook.com/myhdl and Twitter.com/hdltweets.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factorsthat would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Source: Corgenix Medical Corp.

Corgenix Medical Corp.Company Contact:Corgenix Medical Corp.William Critchfield, 303-453-8903Senior VP and CFOwcritchfield@corgenix.comorMedia Contact:Armada Medical MarketingDan Snyders, 303-623-1190 x230Vice President and Public Relations Supervisordan@armadamedical.com

Corgenix Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.

Multi-year collaboration is based on Corgenix’ proprietary atherosclerotic cardiovascularbiomarker technology

DENVER--(BUSINESS WIRE)--Oct. 28, 2013-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.

Under terms of the multi-year agreement, HDL, Inc. has the rights to use Corgenix technology to develop, validate and offer a clinical LDT that may assist clinicians in predicting an increased risk for heart disease in various patient populations. The initial term of the agreement is three years, with annual renewals thereafter based on certain performance requirements.

“This strategic partnership continues our path to fully realize the commercial value of our technology,” said Douglass Simpson, President and CEO of Corgenix. “Our company looks forward to this beneficial partnership, which aims to expand the clinical utility of this advanced cardiac disease biomarker.”

“Our partnership with Corgenix fits perfectly with our strategy to develop best-of-breed biomarkers for the most comprehensive risk factor testing for cardiovascular disease and related diseases,” said Tonya Mallory, President and CEO of HDL, Inc.

LDT’s are at the leading edge of the personalized medicine movement, which includes testing that enables targeted pharmacologic treatment for, and prevention of, heart disease, cancer and other diseases.

Corgenix originally licensed the technology in 2002, and has applied this proprietary technology to the FDA-cleared anti-AtherOx® IgG test kit.

About Health Diagnostic Laboratory, Inc.

Founded in 2008, Health Diagnostic Laboratory, Inc. (HDL, Inc.) is a leader in health management offering a comprehensive test menu of biomarkers of risk factors for cardiovascular disease, diabetes, and related diseases. HDL, Inc.’s systematic approach identifies factors contributing to disease and provides a basis for effective treatment, allowing physicians to more effectively manage patients. Individuals receive a personalized overview of their risk factors along with intensive counseling from expert Clinical Health Consultants at no additional cost, improving compliance and enhancing satisfaction. HDL, Inc. is a CLIA-certified, CAP-accredited laboratory. For more information, visit myhdl.com, and make HDL, Inc. part of your digital lifestyle at Facebook.com/myhdl and Twitter.com/hdltweets.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).

Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factorsthat would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.



Source: Corgenix Medical Corp.

Corgenix Medical Corp.Company Contact:Corgenix Medical Corp.William Critchfield, 303-453-8903Senior VP and CFOwcritchfield@corgenix.comorMedia Contact:Armada Medical MarketingDan Snyders, 303-623-1190 x230Vice President and Public Relations Supervisordan@armadamedical.com

Tight security planned in St. Louis for World Series
by KMOV.com staff
Posted on October 22, 2013 at 8:12 AM

ST. LOUIS -- Fans planning to attend World Series games in St. Louis should expect tight security.

St. Louis police chief Sam Dotson met Monday with state and federal law enforcement officials, government leaders and others. Representatives from the Cardinals and Major League Baseball were also there.

The St. Louis Post-Dispatch reports that while there are no known terrorist threats targeting either St. Louis or Boston, Dotson says agencies are preparing for all hazards.

It was just six months ago that deadly bombings occurred near the finish line of the Boston Marathon, a reminder of the need to secure events involving thousands of people.

St. Louis is hosting the third, fourth and, if necessary, fifth games of the best-of-seven World Series.